A Lingua Franca reader wrote in recently asking that we investigate the growing use of multiple in news stories where many would do just as nicely. Our editor had also noticed a trend toward the ...
Hosted on MSN
Data show teclistamab can benefit many multiple myeloma patients who would have been ineligible for pivotal trial
Teclistamab-cqyv is a T-cell-engaging bispecific antibody that targets multiple myeloma cells via the B-cell maturation antigen (BCMA) receptor. It received accelerated approval in 2022 for patients ...
“Of all of my social media accounts, Twitter offers the most well-rounded view of myself,” says Ashley Brown, a PR consultant with Jones-Dilworth who has spent the past few years immersing herself in ...
Bottom line: Teclistamab-cqyv (Tecvayli) led to clinically meaningful responses in patients with heavily pretreated multiple myeloma who would have been ineligible for the MajesTEC-1 trial, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback